Every two weeks, our US life sciences litigation team shares a 3-minute video update, The Pharma 5, on five hot topics of interest to pharmaceutical and medical device in-house counsel and business leaders.

Our holistic industry approach means we cover it all—commercial cases, MDLs, IP, product liability, FDA and HHS guidance and regulation, dispute resolution, class actions, investigations, antitrust, unfair competition, false advertising, cyber security, criminal probes—and whatever else you need to know now about pharma and med device litigation.

We hope you enjoy Norton Rose Fulbright’s The Pharma 5—and feel free to reach out if we can be of any assistance.

Video updates

List of pages

Brandt Vernon

Pharma 5 | Heat wave relief: Courts around the country keeping cool with defense rulings

In this month's Pharma 5, Brandt Vernon, an associate in Dallas whose practice focuses on pharma and mass tort disputes, discusses punitive damages, class certification, specific causation and judicial integrity.

Jackie Karama

Pharma 5 | Washington knocks out wobbly D2C exception to worthy Learned Intermediary

In this month's Pharma 5, Los Angeles associate Jackie Karama discusses clinical trials, consumer sales, NDA regulation, the Orphan Drug Act and Learned Intermediary.

The Pharma 5

Pharma 5 | What to know now in Pharma and Med Device litigation

In this month’s Pharma 5, Dallas associate Madison Gaona discusses PE-PUR foam, drug discounts, failure to warn and more.

Kevin Yankowsky

Pharma 5 | Game over? Never. A nursing home FCA case gets a fifth look and OTCs shoot for a new target audience

Kevin Yankowsky discusses: the False Claims Act, FDA notice of noncompliance, failed preemption of a false ad suit, healthcare cost dispute and more.

Geraldine Young

Pharma 5 | Wish you were here: Physicians fess up to fondness for face-to-face over fishbowl sales calls

Geraldine Young discusses: Lone Pine Orders, sales reps, Indian Nation Arbitration and more.

Darryl Anderson

Pharma 5 | Basic instinct: Securities class by presumption

Darryl Anderson discusses: Securities class certification, trade secrets injunction, securities fraud scienter, antitrust dismissal and more.

Chris Conatser

Pharma 5 | No more worry lines: A trade-secret battle over Botox gets smoothed out

Senior associate Chris Conatser discusses: Botox settlement, Federal Circuit streaming, FCA liability, pelvic mesh summary judgment and 510(k) evidence.

Alicia Grant

Pharma 5 | Save your strikes: Positive pharma karma points to potentially favorable jury pool

Alicia Grant discusses: Preemption, an LA judge sued, digital pharma, innovator liability and class damages.

Allison Lange Garrison

Pharma 5 | Cyber criminals phishing for settling parties

Allison Lange Garrison, a business and life sciences litigator, discusses: Cyber criminals phishing for settling parties and WTO’s call to waive COVID-19 vaccine patent protections.

Ellie Norris

Pharma 5 | Welcome to The Wire: 3rd Circuit Tackles Drug Safespace

Ellie Norris, whose practice focuses on pharma MDLs and complex litigation discusses: Robocalls II, choice of law, stem cells as drugs, vaccine manufacturing and more.

Farooq Tayab

Pharma 5 | A Colorado bankruptcy court reminds everyone to slow your roll

Farooq Tayab, whose practice focuses on product liability and toxic torts, discusses: cannabis, Learned Intermediary, Article III standing, preemption and drug pricing.

Jan Dodd

Pharma 5 | FDA on confusing drug names and the Second Circuits on rogue science

Jan Dodd, whose practice focuses on advising pharmaceutical, medical device and manufacturing companies on product liability and risk, discusses: FDA guidance, drug pricing, Daubert, securities class action and more.

Kathy Lett

Pharma 5 | Hackers gotta hack, Congress didn’t act

Pharma product liability senior counsel Kathy Lett discusses: JPML, patent, pharmacy benefit managers, the PREP Act and cybersecurity.

D'Lesli Davis

Pharma 5 | Resurrected lawsuits, insider trading, lame ducks and Nobel Peace Prize speculation

Pharmaceutical product liability partner D’Lesli Davis discusses: Consumer fraud, insider trading, competing civil and criminal actions, drug pricing and pharma PR.

Jonathan Skidmore

Pharma 5 | Not another dry PDF: Introducing a new 3-minute visual update from our pharma team

Global Co-Head of Life Sciences and Healthcare Jonathan Skidmore discusses: Dear Healthcare Provider Letters, the Hatch-Waxman venue, state attorney generals’ freedom to police drug marketing and more.

Industry:

Practice area:

Contacts

Jonathan B. Skidmore
Jonathan B. Skidmore
Global Co-Head of Life Sciences and Healthcare
Email
jon.skidmore@nortonrosefulbright.com
T: +1 214 855 8038
D'Lesli M. Davis
D'Lesli M. Davis
Head of Life Sciences and Healthcare, US and Co-Head of Product Liability and Consumer Disputes, US
Email
dlesli.davis@nortonrosefulbright.com
T: +1 214 855 8221